Cargando…

Zonisamide Attenuates α-Synuclein Neurotoxicity by an Aggregation-Independent Mechanism in a Rat Model of Familial Parkinson’s Disease

The anti-epileptic agent zonisamide (ZNS) has been shown to exert protective effects in neurotoxin-based mouse models of Parkinson disease. However, it is unknown whether ZNS can attenuate toxicity of familial Parkinson’s disease-causing gene products. In this study, we investigated the effects of Z...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arawaka, Shigeki, Fukushima, Shingo, Sato, Hiroyasu, Sasaki, Asuka, Koga, Kaori, Koyama, Shingo, Kato, Takeo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930669/ https://www.ncbi.nlm.nih.gov/pubmed/24586512 http://dx.doi.org/10.1371/journal.pone.0089076

Ejemplares similares

Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates
por: Arawaka, Shigeki, et al.
Publicado: (2017)

Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein–coupled receptor kinase–dependent manner
por: Hara, Susumu, et al.
Publicado: (2013)

Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces
por: Sasaki, Asuka, et al.
Publicado: (2015)

Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity
por: Wang, Peng, et al.
Publicado: (2016)

UBR5 Gene Mutation Is Associated with Familial Adult Myoclonic Epilepsy in a Japanese Family
por: Kato, Takeo, et al.
Publicado: (2012)

Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization
por: Roostaee, Alireza, et al.
Publicado: (2013)

Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease
por: Suzuki, Keisuke, et al.
Publicado: (2021)

N‐homocysteinylation of α‐synuclein promotes its aggregation and neurotoxicity
por: Zhou, Lingyan, et al.
Publicado: (2022)

Zonisamide for the Treatment of Parkinson Disease: A Current Update
por: Li, Chengqian, et al.
Publicado: (2020)

Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson’s Disease Models
por: Tada, Satoshi, et al.
Publicado: (2022)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity
por: Ysselstein, Daniel, et al.
Publicado: (2017)

Hepatocellular necrosis with prominent regenerative reactions in a zonisamide administrated dog
por: TAKAMI, Yuki, et al.
Publicado: (2020)

Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2012)

An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain
por: Pacheco, C., et al.
Publicado: (2012)

Exploring the Structural Diversity in Inhibitors of α-Synuclein Amyloidogenic Folding, Aggregation, and Neurotoxicity
por: Das, Sukanya, et al.
Publicado: (2018)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan
por: Yoshida, Shino, et al.
Publicado: (2023)

A Comprehensive Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease
por: Kimura, Hideki, et al.
Publicado: (2011)

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease
por: Ueno, Shin-Ichi, et al.
Publicado: (2018)

Comparative whole transcriptome analysis of Parkinson’s disease focusing on the efficacy of zonisamide
por: Naito, Tatsuhiko, et al.
Publicado: (2022)

Polysomnographic and Clinical Parameters before and after Zonisamide Therapy for Parkinson's Disease
por: Miyaue, Noriyuki, et al.
Publicado: (2022)

Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons
por: Taschenberger, Grit, et al.
Publicado: (2011)

Roles of Autophagy in MPP(+)-Induced Neurotoxicity In Vivo: The Involvement of Mitochondria and α-Synuclein Aggregation
por: Hung, Kai-Chih, et al.
Publicado: (2014)

Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide
por: Choi, Mal-Gi, et al.
Publicado: (2018)

Single point mutations at the S129 residue of α-synuclein and their effect on structure, aggregation, and neurotoxicity
por: Pandit, Esha, et al.
Publicado: (2023)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos
por: Lulla, Aaron, et al.
Publicado: (2016)

Non-Cell-Autonomous Neurotoxicity in Parkinson’s Disease Mediated by Astroglial α-Synuclein
por: Chai, MuhChyi, et al.
Publicado: (2019)

Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson's disease
por: Grover, Neeta D., et al.
Publicado: (2013)

Zonisamide in the management of epilepsy in the elderly
por: Romigi, Andrea, et al.
Publicado: (2015)

Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity
por: Carija, Anita, et al.
Publicado: (2019)

Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders
por: Ingelsson, Martin
Publicado: (2016)

Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson’s Disease
por: Kim, Heejeong, et al.
Publicado: (2022)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

A Segmental Copy Number Loss of the SFMBT1 Gene Is a Genetic Risk for Shunt-Responsive, Idiopathic Normal Pressure Hydrocephalus (iNPH): A Case-Control Study
por: Sato, Hidenori, et al.
Publicado: (2016)

Silicate Urolithiasis during Long-Term Treatment with Zonisamide
por: Taguchi, Satoru, et al.
Publicado: (2013)

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease
por: Nishijima, Haruo, et al.
Publicado: (2018)

Genome-wide association study identifies zonisamide responsive gene in Parkinson’s disease patients
por: Cha, Pei-Chieng, et al.
Publicado: (2020)

Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
por: Sano, Hiromi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4m82ijn27k9bt9a6qq390k93sl